Remyelination In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Remyelination is the process by which demyelinated axons are regenerated with new myelin sheaths. This process occurs naturally in the central nervous system (CNS) following demyelination, but often fails in chronic neurodegenerative diseases, leading to persistent neurological deficits.
| Cell Type |
Role |
| Oligodendrocyte Precursor Cells (OPCs) |
Primary cells that differentiate into mature oligodendrocytes |
| Mature Oligodendrocytes |
Produce myelin sheaths |
| Astrocytes |
Support remyelination; can become reactive and inhibitory |
| Microglia |
Clear debris; coordinate inflammatory response |
| Neurons |
Provide signals that promote oligodendrocyte differentiation |
flowchart TD
A[Demyelination] --> B[OPC Recruitment] -->
B --> C[OPC Proliferation] -->
C --> D[OPC Differentiation] -->
D --> E[Myelin Production] -->
E --> F[Axon Remyelination] -->
F --> G[Functional Recovery] -->
B --> H[Failed Remyelination] -->
H --> I[Chronic Demyelination]
| Factor |
Function |
Therapeutic Potential |
| PDGF |
OPC proliferation |
Recombinant protein |
| FGF2 |
OPC proliferation |
Under investigation |
| NT-3 |
OPC survival and differentiation |
Gene therapy |
| IGF-1 |
Oligodendrocyte differentiation |
Mixed results |
| Shh |
OPC specification |
Under investigation |
| Factor |
Mechanism |
Target |
| Lingo-1 |
Blocks OPC differentiation |
Anti-Lingo-1 antibodies |
| Notch1 |
Inhibits oligodendrocyte maturation |
Gamma-secretase inhibitors |
| Wnt/beta-catenin |
Blocks differentiation |
Wnt inhibitors |
| PSA-NCAM |
Prevents OPC-axon contact |
Enzyme treatment |
| Chondroitin sulfate proteoglycans |
Form physical barrier |
Chondroitinase ABC |
MS is characterized by repeated cycles of demyelination and failed remyelination:
- Early MS: Efficient remyelination forms "shadow plaques"
- Chronic MS: Remyelination fails, leading to permanent axonal loss
- Factors contributing to failure: OPC senescence, inhibitory microenvironment, astrocyte scarring
Emerging evidence suggests remyelination may be impaired:
- White matter lesions common in AD
- Oligodendrocyte dysfunction contributes to cognitive decline
- Myelin breakdown precedes neuronal loss
- Demyelination observed in PD brains
- Oligodendrocyte vulnerability to alpha-synuclein
- Potential therapeutic target
- Guillain-Barré syndrome: Often recovers with remyelination
- Charcot-Marie-Tooth disease: Variable remyelination capacity
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
| Agent |
Mechanism |
Stage |
| Anti-Lingo-1 (opicinumab) |
Promote OPC differentiation |
Clinical trials |
| Clemastine |
M1 muscarinic antagonist |
Clinical trials |
| Bromodomain inhibitors |
Epigenetic regulation |
Preclinical |
| Statins |
Immunomodulation |
Mixed results |
- OPC transplantation: Direct cell delivery
- Induced pluripotent stem cells (iPSCs): Personalized cell therapy
- Schwann cell transplantation: For peripheral nervous system
- Electrical stimulation: Promotes oligodendrocyte differentiation
- Environmental enrichment: Activity-dependent myelination
- Dietary interventions: Omega-3 fatty acids, vitamin D
- MRI: Magnetization transfer ratio, T1/T2 relaxation
- PET: Myelin-specific tracers
- Diffusion MRI: Myelin water imaging
- Myelin basic protein (MBP): CSF marker
- Myelin oligodendrocyte glycoprotein (MOG): Autoantibody target
- Neurofilament light chain (NfL): Axonal integrity
¶ Challenges and Future Directions
- OPC senescence: Age-related decline in OPC function
- Astrocyte reactivity: Forms inhibitory scar tissue
- Persistent inflammation: Chronic cytokine environment
- Axonal damage: Loss of survival signals from axons
- Genetic factors: Individual variability in remyelination capacity
- Single-cell genomics: Profiling remyelinating cells
- Organoid models: Human myelin development in vitro
- CRISPR screening: Identifying novel remyelination genes
- Biomaterial scaffolds: Providing structural support
The study of Remyelination In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Franklin RJ, ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008;9(11):839-855.
- Chang A, et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med. 2002;346(3):165-173.
- Plemel JR, et al. The mechanism of demyelination and remyelination in the central nervous system. Brain. 2017;140(8):2146-2156.
- Luo W, et al. Remyelination in Alzheimer's disease. Nat Rev Neurol. 2023;19(11):651-668.
- Fancy SP, et al. Stem cells for heterogeneous oligodendrocyte lineage remyelination. Cell Stem Cell. 2022;29(11):1536-1552.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
5 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
50% |
Overall Confidence: 30%